Previous 10 | Next 10 |
AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA ® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhi...
AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time. A live webcast of the presentation can be acce...
AVEO Pharmaceuticals ( AVEO +3.5% ) is up on below-average volume following the release of final results from the Phase 2 portion of its Phase 1b/2 clinical trial evaluating the combination of Fotivda (tivozanib) and Bristol-Myers Squibb's ( BMY +0.8% ) Opdivo (nivolumab) in patients...
– Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients – -Tivozanib-Nivolumab Combination Generally Well Tolerated - – Data to be Presented at the ESMO 2019 Annual Congress – AVEO Oncology (...
On September 10th, AVEO Oncology ( AVEO ) publicized their analysis of overall survival “OS” in FOTIVDA’s TIVO-3 trial. This trial was a Phase III study comparing FOTIVDA (tivozanib) to Bayer’s ( OTCPK:BAYRY ) Nexavar (sorafenib) in patients with highly refractory...
AVEO stock is gaining momentum this morning after AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported results from the second prespecified analysis of overall survival in the TIVO-3 trial. Boost for Investors Over the course of the past few months, there has been a lot of anticipation wit...
AVEO Oncology (NASDAQ: AVEO ) is up 20% premarket on the heels of the results from the second prespecified analysis of overall survival (OS) in the TIVO-3 trial. More news on: AVEO Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
- 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - AVEO Oncology (NASDAQ: AVEO) today announced results from the second prespecifi...
AVEO Pharmaceuticals (NASDAQ: AVEO ): Q2 GAAP EPS of -$0.02 beats by $0.03 . More news on: AVEO Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO-3 study of tivozanib in advanced kidney cancer, AVEO...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...